Trending...
- Tampa-Based Digital Marketing Agency Launches New Website to Help Local Businesses Grow Online - 118
- California: Governor Newsom announces new tax credits that will generate $2.1 billion investment in world's 4th largest economy
- New PSA Campaign to Address Black Maternal and Infant Mortality in Los Angeles County
SAN JOSE, Calif. - Californer -- Biomed Industries, Inc. (Biomed) announced today that it has entered into an Engagement Agreement with JP Morgan Securities, LLC to serve as its exclusive financial advisor for a potential acquisition of the Company.
With the completion of Biomed's Phase 2A clinical trial, which demonstrated significant efficacy in maintaining cognitive function in patients with mild to moderate Alzheimer's Disease (AD), the Company is well positioned to execute it's Phase 2B and 3 trials and present itself as an acquisition target for large Pharmaceutical companies seeking a viable treatment for AD.
"Where drugs targeting Beta Amyloid as the cause of AD have consistently showed little to no clinical benefit, our Neurogenesis approach has shown real results", said Lloyd L. Tran, Chairman and CEO of Biomed. He continued: "We believe that our Neurogenesis drug, NA-831, acting alone or in conjunction with drugs from Biogen, Eisai, Eli Lily, and others, is an exciting new pathway for the treatment of Alzheimer's Disease. Working with the JP Morgan M&A team allows us to engage with large pharmaceutical companies in a much more strategic manner."
More on The Californer
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of clinical stage drugs for the treatment of Alzheimer's disease. The Company is also developing new applications of AI for drug discovery, clinical trials recruitment and execution, and other mission critical areas in the pharmaceutical and medical device industry. For more information, please visit https://www.biomedind.com
-
CONTACT:
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Michael Willis
Email: media@biomedind.com
With the completion of Biomed's Phase 2A clinical trial, which demonstrated significant efficacy in maintaining cognitive function in patients with mild to moderate Alzheimer's Disease (AD), the Company is well positioned to execute it's Phase 2B and 3 trials and present itself as an acquisition target for large Pharmaceutical companies seeking a viable treatment for AD.
"Where drugs targeting Beta Amyloid as the cause of AD have consistently showed little to no clinical benefit, our Neurogenesis approach has shown real results", said Lloyd L. Tran, Chairman and CEO of Biomed. He continued: "We believe that our Neurogenesis drug, NA-831, acting alone or in conjunction with drugs from Biogen, Eisai, Eli Lily, and others, is an exciting new pathway for the treatment of Alzheimer's Disease. Working with the JP Morgan M&A team allows us to engage with large pharmaceutical companies in a much more strategic manner."
More on The Californer
- Long Beach Parks, Recreation and Marine and Fire Department to Host Water Safety Day
- Terra Divine Skincare Earns Coveted Spot on Organically Becca's Clean Brand Master List
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
- Emmetra Partners with Renesas to Advance Agentic AI-Powered Imaging Solutions
- Gravity to Bring 5-Minute EV Charging to 8 Sites Across Greater LA
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of clinical stage drugs for the treatment of Alzheimer's disease. The Company is also developing new applications of AI for drug discovery, clinical trials recruitment and execution, and other mission critical areas in the pharmaceutical and medical device industry. For more information, please visit https://www.biomedind.com
-
CONTACT:
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Michael Willis
Email: media@biomedind.com
Source: Biomed Industries
0 Comments
Latest on The Californer
- Harvest Properties Acquires Two San Francisco Bay Area Self Storage Facilities for $44.2 Million
- California businesses in near-universal compliance with prohibition of intoxicating hemp products harmful to youth
- California: Governor Newsom announces upgrades to 21 state fish hatcheries to boost salmon populations
- Solaris Energy Infrastructure, Inc. (SEI) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- Risk Rater, Threat Assessment App, gives Users the Same Threat Evaluation as the Rich and Powerful
- Is it Really True That Tariffs Will Raise Car Insurance Rates?
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Coastal Business Systems Wraps Up Successful 2025 Tech Show in Redding
- AdOcto Turns AirBnBs Into High-Impact Advertising Channels
- Zefr Announces Launch of Pre-Screen Brand Safety Solution for Google's Search Partner Network (SPN)
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
- Flexi-View Lending Closes $5.05 Million Residential Acquisition Loan in Billings, Montana
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
- California: Governor Newsom, Superintendent Thurmond announce over $618 million to support another 458 community schools
- California: Governor Newsom announces judicial appointments 5.7.25
- Long Beach to Commemorate its Naval History with Commemorative Community Event
- Long Beach: City Celebrates Inaugural National Home Improvement Month: Love Where You Live
- California sues Trump administration for illegally withholding billions in bipartisan infrastructure funds: 'Another Trump gift to China'
- Tale of two trains: California high-speed rail leaves Texas in the dust